Kuipers Peter J.
Known title: Executive V P& CFOCIK: 0001651691
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Omnicell Set to Release Q3 2026 Results; Guidance Update. Omnicell will publish its third‑quarter 2026 earnings on Oct. 29, 2026. Analysts noted the company beat revenue expectations but issued weaker EBITDA guidance, which may affect the bullish outlook. The stock is currently near its 12‑touch support level of $42.89 and trades below the average analyst target of $57.86.
Transaction History
| CLOV | ▼ Sell | Tax Withholding | 156,856 | $362K | 1/29/2026 | View on chart |
| CLOV | ▼ Sell | Tax Withholding | 217,382 | $791K | 10/29/2025 | View on chart |
| CLOV | ▼ Sell | Tax Withholding | 217,382 | $628K | 7/29/2025 | View on chart |
| CLOV | ▲ Buy | Grant | 326,647 | $0 | 5/19/2025 | View on chart |
| CLOV | ▼ Sell | Tax Withholding | 825,989 | $2.8M | 4/29/2025 | View on chart |
| OMCL | ▼ Sell | Tax Withholding | 2,292 | $166K | 6/15/2023 | View on chart |
| OMCL | ▼ Sell | Tax Withholding | 4,196 | $203K | 12/15/2022 | View on chart |
| OMCL | ▲ Buy | Option Exercise | 4,040 | $179K | 8/26/2022 | View on chart |
| OMCL | ▲ Buy | Option Exercise | 11,460 | $904K | 8/26/2022 | View on chart |
| OMCL | ▼ Sell | Open Market | 19 | $2K | 8/26/2022 | View on chart |
| OMCL | ▼ Sell | Open Market | 15,481 | $1.7M | 8/26/2022 | View on chart |
| OMCL | ▲ Buy | Option Exercise | 11,000 | $487K | 8/22/2022 | View on chart |
| OMCL | ▼ Sell | Open Market | 11,000 | $1.2M | 8/22/2022 | View on chart |
| OMCL | ▼ Sell | Tax Withholding | 4,193 | $474K | 6/15/2022 | View on chart |
| OMCL | ▼ Sell | Tax Withholding | 1,680 | $220K | 3/14/2022 | View on chart |
| OMCL | ▲ Buy | Grant | 19,040 | $0 | 3/14/2022 | View on chart |
| OMCL | ▲ Buy | Grant | 9,988 | $0 | 2/16/2022 | View on chart |
| OMCL | ▼ Sell | Tax Withholding | 3,740 | $0 | 12/15/2021 | View on chart |
| OMCL | ▲ Buy | Option Exercise | 5,640 | $0 | 12/7/2021 | View on chart |
| OMCL | ▼ Sell | Open Market | 991 | $179K | 12/7/2021 | View on chart |
| OMCL | ▼ Sell | Open Market | 4,649 | $844K | 12/7/2021 | View on chart |
| OMCL | ▼ Sell | Open Market | 492 | $89K | 12/7/2021 | View on chart |
| OMCL | ▼ Sell | Open Market | 2,353 | $426K | 12/7/2021 | View on chart |
| OMCL | ▼ Sell | Open Market | 32 | $6K | 12/7/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Clover Health Gains After Earning 5-Star CMS Rating
Clover Health stock rose after the company secured a 5-star rating for its PPO plan from CMS for 2027. This top score supports the company's long-term outlook and may help attract new members. The news follows a period where the stock was trading near its 52-week high, reflecting positive market sentiment.
Clover Health Gains After Earning 5-Star CMS Rating. Clover Health stock rose after the company secured a 5-star rating for its PPO plan from CMS for 2027. This top score supports the company's long-term outlook and may help attract new members. The news follows a period where the stock was trading near its 52-week high, reflecting positive market sentiment.